



Premature termination of a Clinical Trial

Full title of the clinical Trial: Rituximab (Mabthera) in metastatic melanoma

EudraCT Number: 2007-005125-30

Sponsor: Medical University of Vienna

Represented by (name): Wagner Stephan, Univ.Doz.Dr.

Reason for premature termination of the clinical trial:

The only reason is, that patient recruitment was not sufficient to meet the planned patient numbers within the planned study period. This is due to the fact that complete remissions, i.e. major inclusion criterion for this trial, in metastatic melanoma patients are so infrequent.

Study results (if available):

**Date and Signature of Sponsor
representative:**

June, 1st, 2021